B y now, it's almost old news: big data will transform med icine. It's essential to remember, however, that data by themselves are useless. To be useful, data must be analyzed, interpreted, and acted on. Thus, it is algorithms -not data sets -that will prove transformative. We believe, there fore, that attention has to shift to new statistical tools from the field of machine learning that will be critical for anyone practic ing medicine in the 21st century.
First, it's important to under stand what machine learning is not. Most computerbased algo rithms in medicine are "expert systems" -rule sets encoding knowledge on a given topic, which are applied to draw conclusions ry agencies will pay particular at tention to preclinical safety and toxicity studies and assessments of unexpected adverse events dur ing clinical trials and after licen sure. The case for licensure may be established through tradition al clinical efficacy trials, but de clining case counts or an urgent need for intervention may neces sitate a different pathway. Alter natives include using efficacy data from studies in animals combined with human immunogenicity data or bridging to an asyetundefined immune correlate of protection. Human challenge studies have been proposed in order to augment information from efficacy trials, assist in exploring immune cor relates of protection, or generate efficacy data if natural transmis sion substantially declines. In the absence of a clear understanding of the frequency of adverse neu rologic outcomes or the persis tence of ZIKV in biologic fluids, however, human ZIKV challenge is ethically complex.
Other flavivirus vaccines have been licensed, including those against yellow fever (live attenu ated), Japanese encephalitis (inac tivated, live chimeric, live atten uated), tickborne encephalitis (inactivated), and dengue (live chi meric). Some have validated surro gates of protection, and all are based on neutralizing antibody. A neutralizing antibody titer of 1 in 10 is the surrogate of protection for the Japanese and tickborne encephalitis vaccines; for yellow fever, the titer is between 1 in 10 and 1 in 50. Preclinical ZIKV studies suggest that a titer of 1 in 10 for mice and approximately 1 in 100 for nonhuman primates pro tected against ZIKV challenge. 1, 2 If these figures translate to hu mans, developing a ZIKV vaccine is very feasible.
The time required to develop a safe, efficacious ZIKV vaccine will be determined by prior experience with the selected technology, the continuation of outbreaks, and the required scaleup of manufactur ing. Ultimately, developing, licens ing, and deploying a vaccine ca pable of affecting the current epidemic will require seamless coordination among developers, regulatory agencies, the WHO, and national health authorities, along with a robust monetary commit ment from governments and fund ing agencies.
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Predicting the Future n engl j med 375;13 nejm.org September 29, 2016 about specific clinical scenarios, such as detecting drug interac tions or judging the appropriate ness of obtaining imaging. Ex pert systems work the way an ideal medical student would: they take general principles about med icine and apply them to new pa tients.
Machine learning, conversely, approaches problems as a doctor progressing through residency might: by learning rules from data. Starting with patientlevel observa tions, algorithms sift through vast numbers of variables, looking for combinations that reliably pre dict outcomes. In one sense, this process is similar to that of tra ditional regression models: there are outcomes, covariates, and sta tistical functions linking the two. But where machine learning shines is in handling enormous numbers of predictors -sometimes, re markably, more predictors than observations -and combining them in nonlinear and highly in teractive ways. 1 This capacity al lows us to use new kinds of data, whose sheer volume or complex ity would previously have made analyzing them unimaginable.
Consider a chest radiograph. Some radiographic features might predict an important outcome, such as death. In a standard sta tistical model, we might use the radiograph's interpretation -"normal," "atelectasis," "effusion" -as a variable. But instead, why not let the data speak for them selves? Leveraging dramatic ad vances in computational power, digital pixel matrixes underlying radiographs become millions of individual variables. Algorithms then go to work, clustering pixels into lines and shapes and ulti mately learning contours of frac ture lines, parenchymal opacities, and more. Even traditional insur ance claims data can take on a new life: diagnostic codes trace an intricate, dynamic picture of pa tients' medical histories, far richer than the static variables for coex isting conditions used in standard statistical models.
Of course, letting the data speak for themselves can be problematic. Algorithms might "overfit" pre dictions to spurious correlations in the data, or multiple collinear, correlated predictors could pro duce unstable estimates. Either possibility can lead to overly op timistic estimates of the accuracy of a model and exaggerated claims about realworld performance. These concerns are serious and must be addressed by testing models on truly independent vali dation data sets, from different populations or periods that played no role in model development. In this way, problems in the model fitting stage, whatever their cause, will show up as poor performance in the validation stage. This prin ciple is so important that in many datascience competitions, valida tion data are released only after teams upload their final algo rithms built on another publicly available data set.
Another key issue is the quan tity and quality of input data.
Machine learning algorithms are highly data hungry, often re quiring millions of observations to reach acceptable performance levels. 2 In addition, biases in data collection can substantially affect both performance and gen eralizability. Lactate might be a good predictor of the risk of death, for example, but only a small, nonrepresentative sample of patients have their lactate levels checked. Private companies spend enormous resources to amass highquality, unbiased data to feed their algorithms, and exist ing data in electronic health rec ords (EHRs) or claims databases need careful curation and pro cessing to become usable.
Finally, machine learning does not solve any of the fundamental problems of causal inference in observational data sets. Algo rithms may be good at predict ing outcomes, but predictors are not causes. 3 The usual common sense caveats about confusing cor relation with causation apply; in deed, they become even more important as researchers begin including millions of variables in statistical models.
Machine learning has become ubiquitous and indispensable for solving complex problems in most sciences. In astronomy, al gorithms sift through millions of
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Predicting the Future n engl j med 375;13 nejm.org September 29, 2016 images from telescope surveys to classify galaxies and find super novas. In biomedicine, machine learning can predict protein struc ture and function from genetic sequences and discern optimal diets from patients' clinical and microbiome profiles. The same methods will open up vast new possibilities in medicine. A strik ing example: algorithms can read cortical activity directly from the brain, transmitting signals from a paralyzed human's motor cor tex to hand muscles and restor ing motor control. 4 These advanc es would have been unimaginable without machine learning to pro cess realtime, highresolution physiological data.
Increasingly, the ability to transform data into knowledge will disrupt at least three areas of medicine. First, machine learning will dramatically improve the abil ity of health professionals to es tablish a prognosis. Current prog nostic models (e.g., the Acute Physiology and Chronic Health Evaluation [APACHE] score and the Sequential Organ Failure As sessment [SOFA] score) are re stricted to only a handful of vari ables, because humans must enter and tally the scores. But data could instead be drawn directly from EHRs or claims databases, allow ing models to use thousands of rich predictor variables. Does do ing so lead to better predictions? Early evidence from our own on going work, using machine learn ing to predict death in patients with metastatic cancer, provides some indication: we can precisely identify large patient subgroups with mortality rates approaching 100% and others with rates as low as 10%. Predictions are driven by finegrained information cutting across multiple organ systems: infections, uncontrolled symp toms, wheelchair use, and more. Better estimates could transform advance care planning for patients with serious illnesses, who face many agonizing decisions that depend on duration of survival. We predict that prognostic algo rithms will come into use in the next 5 years -although prospec tive validation will take several more years of data collection.
Second, machine learning will displace much of the work of ra diologists and anatomical pathol ogists. These physicians focus largely on interpreting digitized images, which can easily be fed directly to algorithms instead. Massive imaging data sets, com bined with recent advances in computer vision, will drive rapid improvements in performance, and machine accuracy will soon exceed that of humans. Indeed, radiology is already partway there: algorithms can replace a second radiologist reading mam mograms 5 and will soon exceed human accuracy. The patient safety movement will increasing ly advocate the use of algorithms over humans -after all, algo rithms need no sleep, and their vigilance is the same at 2 a.m. as at 9 a.m. Algorithms will also monitor and interpret streaming physiological data, replacing as pects of anesthesiology and criti cal care. The time scale for these disruptions is years, not decades.
Third, machine learning will improve diagnostic accuracy. A recent Institute of Medicine report highlighted the alarming frequen cy of diagnostic errors and the lack of interventions to reduce them. Algorithms will soon gen erate differential diagnoses, sug gest highvalue tests, and reduce overuse of testing. This disruption will happen more slowly, over the next decade, for three reasons: first, the standard for diagnosis is unclear in many conditions (e.g., sepsis, rheumatoid arthri tis) -unlike binary judgments in radiology or pathology (e.g., malignant or benign) -making it harder to train algorithms. Sec ond, highvalue EHR data are of ten stored in unstructured for mats that are inaccessible to algorithms without layers of pre processing. Finally, models need to be built and validated individ ually for each diagnosis.
Clinical medicine has always required doctors to handle enor mous amounts of data, from macrolevel physiology and be havior to laboratory and imaging studies and, increasingly, "omic" data. The ability to manage this complexity has always set good doctors apart from the rest. Ma chine learning will become an indispensable tool for clinicians seeking to truly understand their patients. As patients' conditions and medical technologies become more complex, the role of machine learning will grow, and clinical medicine will be challenged to grow with it. As in other indus tries, this challenge will create winners and losers in medicine. But we are optimistic that patients, whose lives and medical histories shape the algorithms, will emerge as the biggest winners as ma chine learning transforms clinical medicine.
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